Studies from Kyushu University Have Provided New Information about Chronic Heart Failure (Long-term Treatment With Sacubitril/valsartan In Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction - Open-label Extension of the...).

A study conducted by Kyushu University in Fukuoka, Japan, examined the long-term treatment of sacubitril/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction (HFrEF). The study enrolled 150 patients who received sacubitril/valsartan in addition to optimal background heart failure therapy. The researchers found that long-term sacubitril/valsartan at doses up to 200 mg, b.i.d., was safe and well-tolerated in Japanese patients with chronic HFrEF. The study concluded that sacubitril/valsartan has a positive risk-benefit profile for these patients. [Extracted from the article]